Bridging the gap between innovation and capital
Zealand Pharma
Focus on Biotech Therapeutic Companies
Program
Zealand Pharma is a Denmark-headquartered biotech company with U.S. operations, focused on metabolic health, with obesity as its lead indication. Right now, they are especially excited to meet teams with differentiated obesity assets that go beyond GLP-1.
OPPORTUNITY
LaunchBio, Citrin Cooperman, and Silicon Valley Bank, a Division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with Zealand Pharma.
Zealand is interested in enabling technology platforms for tissue-targeted delivery of biologics, using oligonucleotides, antibodies or peptides as the payload, to tissues such as adipose, skeletal muscle and the CNS. Platforms capable of generating antibody-peptide and oligonucleotide-peptide conjugates are of particular interest. For both assets and technologies, they look for in vivo proof of concept at a minimum.
Applications will be selected based on meeting the following criteria:
Geography
Open to opportunities in the USA
Company Type
Preclinical-stage and beyond, with in vivo POC as the minimum bar. Applies to both therapeutic assets and platform technologies.
Stage
Companies seeking funding for Seed, Series A and beyond. Prefer to work with companies with Development Candidates, but can look earlier.
Modalities of Interest
- Peptide therapeutics and payloads
- Antibodies and other biologics
- Oligonucleotide-based therapeutics
- Antibody-peptide conjugates
- Oligonucleotide-peptide conjugates
- Tissue-targeted delivery platforms (adipose, skeletal muscle, CNS)
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Citrin Cooperman and Silicon Valley Bank, a division of First Citizens Bank.